Zelira Therapeutics Limited

Zelira Therapeutics Limited is a biopharmaceutical company specializing in the research, development, and commercialization of cannabinoid-based medicines. The company leverages pharmaceutical expertise to develop proprietary therapies targeting medical conditions with significant unmet needs, including insomnia, autism, and chronic non-cancer pain. Zelira Therapeutics operates a dual focus, delivering prescription (Rx) cannabinoid medicines that undergo rigorous clinical validation, and also offering over-the-counter (OTC) products to a broader market. The company maintains a portfolio of clinically validated products as well as a pipeline of candidates in various stages of development, positioning it to enter and expand within the global market for cannabinoid therapeutics. Headquartered in Perth, Western Australia, Zelira is recognized for its evidence-based approach, commitment to regulatory compliance, and the application of world-class science in clinical trials. Its activities are significant in the emerging field of cannabinoid pharmaceuticals, providing new treatment options for patients and addressing previously underserved segments within the healthcare sector.